Carmichael Roberts is a General Partner at North Bridge Venture Partners and the chairman of the board of 1366 Technologies Inc.

Prior to joining North Bridge, Carmichael co-founded and served as the President and Chief Executive Officer of WMR Biomedical, Inc., a company that develops implantable medical materials.
Before WMR Biomedical, Carmichael co-founded and served as the President and Chief Executive Officer of Surface Logix, Inc., a drug optimization company. 
Carmichael has also co-founded and served as a director of several other ventures, including Ancora Pharmaceuticals, Inc., a carbohydrate materials company, Nano-Terra, Inc., an electronics and industrial materials company, and Diagnostics For All, Inc., a non-profit organization that is developing a materials platform to make low cost diagnostics for the poor.

Prior to his entrepreneurial career, Carmichael worked in business development at GelTex Pharmaceuticals, Inc., which was acquired by Genzyme for $1.3 billion. 
Prior to GelTex, Carmichael was responsible for new product and business development in the Sentry Products Specialty Materials Division of Union Carbide Corporation.

Carmichael is mainly interested in companies that make products using chemistry, materials science and/or materials engineering.
He primarily focuses on very early stage ventures, including helping founders launch companies from initial formation.

Carmichael received his B.S. and Ph.D. in organic chemistry from Duke University and completed his postdoctoral fellowship at Harvard University. 
Carmichael also received his M.B.A. from the MIT Sloan School of Management.